Overview:
DNA repair is a multistep process in which many different proteins must work together in order to maintain the integrity of the genome. Developing biomarkers of DNA repair can help doctors determine which treatments work best for a patient's cancer. Currently, most PARP inhibitors target PARP1/2, which are critical enzymes in DNA repair. PARP enzymes repair single-strand breaks through a pathway called the short-patch BER. Moreover, changes to other repair pathways are affecting this pathway and increasing its reliance on PARP enzymes.
To Get Complete Industry Insights, Grab Sample PDF Copy Here: https://bit.ly/3SYgHeK
Market Drivers:
Growing cases of chronic disease such as cancer across the globe is projected to propel growth of the global PARP inhibitor biomarkers testing product market over the forecast period. Cancer is one of the chronic diseases of class that has no growth control cells. As per the National Cancer Institute of the U.S., the country was estimated to witness 1,806,590 new cancer cases in 2020, with 606, 520 cancer deaths. Thus, demand for PARP inhibitor biomarkers testing is increasing driving the market growth.
Moreover, growing R&D of new treatments is also expected to propel growth of the global PARP inhibitor biomarkers testing product market over the forecast period.
Market Restraints:
High cost of test kits, strict regulatory demand, and product recalls are expected to hinder growth of the global PARP inhibitor biomarkers testing product market over the forecast period.
Regional Analysis:
North America is anticipated to witness substantial growth in the global PARP inhibitor biomarkers testing product market over the forecast period. This is due to advanced medical facilities, launch of new products, and strong presence of major market players in the region.
Asia Pacific is also projected to witness substantial growth in the global PARP inhibitor biomarkers testing product market over the forecast period, owing to rise in investments by market players in emerging economies to cater the demand and to strengthen their market presence across the region.
Key Players:
Key players active in the global PARP inhibitor biomarkers testing product market are BPS Bioscience, Inc., Myriad Genetics, Inc., NeoGenomics Laboratories, Inc., Invitae Corporation and F. Hoffmann-La Roche AG
In March 2022, the PARP inhibitor, Lynparza of AstraZeneca and MSD received approval from the U.S. Food and Drug Administration (FDA), for treatment of patients with germline BRCA-mutated HER2-negative high risk break cancer.
No comments:
Post a Comment